Komori
Dividends4527ROHTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice of Revision to Dividend Forecast (Increase)

The year-end dividend forecast for the fiscal year ending March 2026 has been increased by ¥2, from ¥23 to ¥25 per share. Accordingly, the annual dividend forecast has also been increased from ¥44 to ¥46.

Worth reading
58In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
2
Yen per share
Wording
Definitive
How definitive the wording is.

Dividend per share

Fiscal year ending March 2026
46YenRevised annual dividend per sharePrevious forecast ¥44, change ¥+2(+4.6%)
Previous-period resultsPrevious forecastAfter revision

Each vertical step represents one dividend payment, and the total height of the accumulated steps represents the annual dividend for the period. For periods showing only the annual amount, the payment breakdown is not provided, so only the end point is plotted.

Dividend per share¥¥23→¥25+8.7%
Breakdown of Regular, Commemorative and Special DividendsRegular dividend only (no commemorative or special dividend stated)
Dividend policy

The Company considers the stable and continuous return of the results generated through its business activities to shareholders to be one of its key priorities, and its basic policy is to pay dividends in line with earnings.

Dividend per share
ItemDetails
Dividend per share¥23.00 → ¥25.00(8.70%)
Total Annual Dividends¥44.00 → ¥46.00(4.55%)
Previous-period results (per share)Interim ¥16.00 / End of period ¥20.00 / Annual ¥36.00
Breakdown of Regular, Commemorative and Special DividendsRegular dividend only (no commemorative or special dividend stated)
Dividend policyThe Company considers the stable and continuous return of the results generated through its business activities to shareholders to be one of its key priorities, and its basic policy is to pay dividends in line with earnings.
Fiscal Period CoveredFiscal year ending March 2026
Items this document does not state (6)
Total dividendsRecord dateEffective dateSource of dividendsPayout ratioWhether Submission to the General Meeting of Shareholders Is Required

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To promote the return of profits to shareholders based on the earnings forecast for the fiscal year ending March 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Revision to Dividend Forecast (Increase) | ROHTO PHARMACEUTICAL CO.,LTD. (4527) timely disclosure | Komori